{"name":"Atossa Therapeutics, Inc.","slug":"atossa-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1758,"revenueGrowth":-99.7,"grossMargin":-7431.9,"rdSpend":21185000,"netIncome":-34770000,"cash":41299000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AT-301A","genericName":"AT-301A","slug":"at-301a","indication":"Other","status":"phase_1"},{"name":"AT-301B","genericName":"AT-301B","slug":"at-301b","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AT-301A","genericName":"AT-301A","slug":"at-301a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-301B","genericName":"AT-301B","slug":"at-301b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNTlhaNk5rU2p4MlZjdVBoaE1wUHVtdlRRV3JSeEp6ZFQyd1hoNWVmREt3ZW03Ty1PTjRzMXVSS2c3cVIyb2ZfVkd1bW81WDhkMG5PYWQ5V3V5OGdtTnV2WVppSnNneFdHcUNiMVVrU2FzbGZiQnNiUlY5eEViajZuVEpXUkdWalp6a2ZpU0h1aE5iNTQxdlZrb3EtRlNlX3hpZlFEQmJKcl85SVhVaVJ0a0pEYllaWWR2ZE9pMg?oc=5","date":"2026-03-30","type":"pipeline","source":"stocktitan.net","summary":"[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - stocktitan.net","headline":"[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQMmh2VUd3a0JadTI2MF9tNzhfMnhCRTc3b2dEMGp5YmY4aTVNeTVwRFpjRDFUWTVmQXYwMHgzWGZhaGFSUUxJaGdXOWFueF9kMl90ZXA5dEFMQ3ZJQ3d3Z0MwVi1kY1lNZGQxbzZPNzh1OElWTnFVaC1rWjdwMkhMMkwyUmkzSFpBLS1IaEJDdmRhbGV6d3dZaUJweXMyNGcwc1JCaHNHXy0wMXJRblNHc3lkZjNuZTg1bEU3TTJOamx5eFlITVBiczVFaVcycG1DQ2JRNkVuT205RHM?oc=5","date":"2026-01-27","type":"earnings","source":"simplywall.st","summary":"Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook - simplywall.st","headline":"Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook","sentiment":"neutral"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPLTdqVDB1QXBRWlRkY1l4X1RPMHJzVm1yMW93WDgyOGNrcWJtMW9fN2tWUVJmMGJuZWxhRzkyMVI1QXYyUXdvdGs1b0xJbFBZcHA4UTBfUzZmTlc5dU5iNVR6TnJxTlo3RFZBV2FsR1RvTmpCcXFDM2pyWWlsV0V5dFBhT3pIaUpFNnZUUjNlWHZuaVlJbFlRV2xPdk9PZFQ5SVJ3R20tNHhjODVZbHFXdF9NbmgtY2ZYSW5LUzUxTmNFSUJFaS1mQ1h1ZHZTRENUakNRTGh4b2YycTE4SnJpQ05GTWVvOF9iZm5hXzNjdWxGeElZc1NpMHN0VEUtSjVRZ25CRjQxN0c?oc=5","date":"2026-01-16","type":"regulatory","source":"PR Newswire","summary":"Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - PR Newswire","headline":"Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystro","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPLXpPckRvQy1hMlVjTTdBeXhMb3o1TGVpNHBZaWRBemRPRVd0Rk5aOXVWY0NFd0lXRm81M1lWalp2RjM1UFdqcTI3dkRzWW5PbDVubGlwNDBsMFdabk1HSlRfOElQQVdDQUNiOFJsdXhaU3F2ekdydnRzRWJMdGdaczZKc21Rb2daeFdBUzdsendweFNDa3hrc01fdEI2Rll6c0N5Q21xLTc4UXdPcG5sYTVyTVRBdHhfcEZteldFQ3BEX1JtSThtMHhJRHpPcUxxanNRUEVvRjRFYXhLWU1lam5JUE9pck85TXU2Q0ZaZFk2aXRs?oc=5","date":"2025-12-04","type":"regulatory","source":"PR Newswire","summary":"Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum - PR Newswire","headline":"Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum","sentiment":"neutral"},{"date":"2025-12-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-03","type":"pipeline","source":"simplywall.st","summary":"Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth? - simplywall.st","headline":"Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxPd3ZwcElXOUZ0c0FucmUxdVduWUVUaTRBZkNzNEVqU2JHbmpfcGZpMXhLWEZEellmUW02TUpRYVdwTUpRb0J6cEpEUWZJWGNUR2tTM1VNTlk1V1pva0w4R2dGTTF6c1ZUOWVoQ1N5eEhaYjRJX1hxU1dUdFlmSndVaUYyRlA1MlhVdVhDb0ZzT2d1RFp5MVRicjJHLXVSVWd3WU5YVnVjTnRYYzBrQ2hMVzB2SUxvNnhnbnBKZ2ozdjlUNE9uUWFXWW55bnd2bDhscUVuU25KR3lhRUMyUDdpSTJBUEg3Rng5Zk1oeS10NmMzUWd1VmU0VUktbVlwZzFrSHM0UkJNaFNrLUFDWkxDWG1zb2g0aTM0ZnYzYmNqcEotX09RQ0VFWWdWYzZnV0lueFN4QUFLZlV3SXZWN0FyOHlRR0xKeS1UVVFhYw?oc=5","date":"2025-12-02","type":"trial","source":"PR Newswire","summary":"Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma - PR Newswire","headline":"Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1758,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":1758,"period":"2015-12-31"},{"value":525954,"period":"2014-12-31"},{"value":1115900,"period":"2013-12-31"},{"value":483342,"period":"2012-12-31"},{"value":1500,"period":"2011-12-31"}],"grossProfit":-130653,"grossProfitHistory":[],"rdSpend":21185000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-34770000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":41299000,"cashHistory":[],"totalAssets":47608000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}